Skip to content

Study of serum magnesium levels in hypertensive disorder and normal pregnancy and its correlation with feto-maternal outcome.

Study of serum magnesium levels in Preeclampsia and in normal pregnancy and its correlation with feto maternal outcome.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064888
Enrollment
180
Registered
2024-03-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O14- Pre-eclampsia

Interventions

Intervention1: magnesium: only one sample taken at the time of delivery Control Intervention1: Serum Magnesium: Magnesium is a major intracellular divalent cation and plays an essential physiologic ro

Sponsors

AVBRH DMIHER
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Pregnant women with clinically diagnosed preeclampsia with gestational age above 28 weeks. 2)Singleton pregnancy. 3)Those patients who are willing to get enrolled in the study.

Exclusion criteria

Exclusion criteria: 1.Women with essential hypertension, chronic renal disease, liver disease, sickle cell anemia, diabetes mellitus, Rh isoimmunization, peptic ulcer disease, patients on magnesium containing antacids, retroviral disease patients were excluded. 2.In addition women with multiple gestation dietary magnesium supplementation found in some prenatal multivitamin combinations. 3.Pregnant women who smoke cigarette or consume alcohol were also excluded.

Design outcomes

Primary

MeasureTime frame
Comparison of serum magnesium levels in preeclampsia and normal pregnancy decline in serum magnesium level with increasing gestational age. the fetal outcome with decreased serum magnesium level. Timepoint: at the time of delivery

Secondary

MeasureTime frame
maternal outcomes- aph, pph, preterm delivery, iufd. fetal outcomes- still birth , nicu admission, intrauterine fetal death.Timepoint: at the time of delivery after the period of viability has been crossed

Countries

India

Contacts

Public ContactDr Aishwarya Gupta

Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha

sandhyapajai@gmail.com9823686669

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026